الفهرس 
Hepatitis C virusOnly 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Hepatitis C virus is the etiological agent of hepatitis C which is an infectious disease affecting the liver. It has high tendency to cause chronic progressive hepatic damage and HCC. Hepatocellular carcinoma is considered the commonest primary hepatic cancer, the fifth most frequent cancer worldwide and the third cause of cancer related mortality.
Cancer stem cells (CSCs such as CD133, CD90 and CK19) are subset of cells displaying stem cell-like properties; marked proliferative ability, apoptosis-resistance, self-renewal and ability to differentiate into non-tumorigenic cancer.
This study aimed to investigate the expression of CSC markers as CD133, CD90 and CK19 in HCC patients and HCV infected patients before and after receiving antiviral therapy, evaluate their sensitivity in detection of HCC and assess their role in predicting the prognosis of HCC patients.
This study was carried out at Microbiology and Immunology Department, in cooperation with Hepatology Department, National liver institute, Menoufia University during the period from July 2017 to October 2018.
The current study included 75 participants (51 males and 24 females) who were selected randomly from those attending National Liver Institute and classified into four groups: group I: 30 HCC patients (20 males and 10 females), group II: 15 HCV patients (9 males and 6 females) before receiving antiviral therapy (sofosbuvair and daclatasvir for 3 months), group III: 15 HCV patients (11 males and 4 females) after receiving antiviral therapy. group IV: 15 apparently healthy individuals (11 males and 4 females) as a control group.
All participants were subjected to:
1. History taking.
2. Complete clinical examination.
3. Laboratory investigations; (Complete blood count, Prothrombin concentration, INR, Liver and renal function tests and Hepatitis markers; hepatitis C virus antibody (anti HCV), Hepatitis B surface antigen (HBsAg).
4. Measurement of serum Alpha fetoprotein (AFP) level by two-step sandwich solid phase enzyme immunoassay.
5. Detection of HCV RNA by quantitative Real Time PCR.
6. Detection of CSC markers (CD133, CD90 and CK19) by quantitative Real Time PCR.
The results of the present study revealed that:
The mean values of CD133 (4.06±2.53), CD90 (6.70±3.97) and CK19 (10.2±6.31) were highly significantly increased in HCC patients than in HCV patients before receiving treatment (0.51±0.37 vs. 1.17±1.01 vs. 0.93±0.58) and those after receiving treatment (0.23±0.22 vs. 0.32±0.25 vs. 0.46±0.43) and controls (0.08±0.12 vs. 0.15±0.12 vs. 0.42±0.28).
The mean values of AFP level were highly significant increased in HCC group (393.6±120) in comparison to HCV patients before receiving.